StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Monday morning. The firm issued a hold rating on the stock.

Several other brokerages have also recently weighed in on EKSO. Lake Street Capital initiated coverage on shares of Ekso Bionics in a research note on Monday, June 24th. They set a buy rating and a $2.50 price target on the stock. HC Wainwright reaffirmed a buy rating and issued a $10.00 target price on shares of Ekso Bionics in a report on Tuesday, July 30th.

Ekso Bionics Stock Performance

Shares of EKSO opened at $1.25 on Monday. The firm has a market capitalization of $22.72 million, a P/E ratio of -1.29 and a beta of 1.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77. Ekso Bionics has a one year low of $0.62 and a one year high of $3.13. The business has a fifty day moving average of $1.13 and a 200 day moving average of $1.22.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The firm had revenue of $4.95 million for the quarter, compared to the consensus estimate of $5.34 million. During the same quarter in the prior year, the firm earned ($0.31) earnings per share. As a group, sell-side analysts anticipate that Ekso Bionics will post -0.42 EPS for the current year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC grew its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 as of its most recent filing with the Securities & Exchange Commission. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.